ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

A video interview with atai management will be available at 8:30 a.m. (ET) at . The archived video interview will be available in the “Events” section of the atai website at .

About atai Life Sciences



atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai's business model combines funding, technology, scientific, and regulatory expertise with a focus on innovative compounds, including psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Greg Weaver

Chief Financial Officer

Email: 

Media Contact:

Allan Malievsky

Senior Director, External Affairs

Email: 



EN
01/08/2022

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Positive Topline Results from an Exploratory Pha...

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) asses...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

AtaiBeckley To Host Virtual Investor Day on March 6, 2026 NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders....

February 20, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chie...

February 19, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley To Participate in Upcoming Investor Conferences

AtaiBeckley To Participate in Upcoming Investor Conferences NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March. TD Cowen ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scie...

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company present...

January 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch